Tiny trial tests new lead for implanted defibrillator

NCT ID NCT06592001

Ongoing Disease control Sponsor: AtaCor Medical, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early study tests a new type of lead (a wire) for an implantable cardioverter-defibrillator (ICD) in 19 people who need one. The lead is placed under the breastbone to deliver a shock if the heart beats dangerously fast. The goal is to see if it is safe and works well enough to plan a larger study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AtaCor EV-ICD Atala™ lead (implanted device)
What this could lead to: If successful, this could lead to a safer, more effective way to deliver life-saving shocks from an implantable defibrillator to prevent sudden cardiac death.
What could go wrong: This is a very small, early feasibility study with only 19 people and no control group. The device may not work as expected or could cause complications like infection or lead failure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VENTRICULAR ARRYTHMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiac rhythm disease ventricular fibrillation ventricular tachycardia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

VENTRICULAR ARRYTHMIA VENTRICULAR FIBRILLATION VENTRICULAR TACHYCARDIA

Contacts and locations

Locations

Christchurch Hospital

Christchurch, New Zealand
Sanatorio Italiano

Asunción, Paraguay
University Hospital Center Split

Split, 21000, Croatia

More trials for these conditions

Other studies related to the condition(s) this trial covers.